Funding for this research was provided by:
Eli Lilly and Company
Text and Data Mining valid from 2020-01-07
Received: 10 November 2019
Accepted: 26 December 2019
First Online: 7 January 2020
Ethics approval and consent to participate
: The study was approved by NHS Research Ethics Service (reference 09/H1307/110). Written consent was obtained from participants before any study activities took place.
: Not applicable.
: M Mayr filed and licensed patent applications on miRNAs as biomarkers (EP15193448.6, EP2776580 B1, DE112013006129T5, GB2524692A, EP2576826 B, JP2013-513740). M. Mayr filed and licensed patent applications on miRNAs as biomarkers (EP15193448.6, EP2776580 B1, DE112013006129T5, GB2524692A, EP2576826 B, JP2013-513740).RF Storey reports institutional research grants/support from AstraZeneca and GlyCardial Diagnostics; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, GlyCardial Diagnostics, Haemonetics, Idorsia, Novartis, Portola and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer and Medscape. R. Ajjan. received honoraria and educational and research support from Abbott Diabetes Care, AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, Sanofi, MSD, and Boehringer Ingelheim. The other authors report no relevant disclosures.